Les Sulewski – Truist Securities

Truist Securities

A Truist Securities analyst with 19 tracked ratings across 9 distinct tickers has a 42.9% success rate on the captured sample, primarily issuing 13 bullish ratings and 1 bearish rating in the covered sectors.

Aggregated from multiple market-data sources

Total ratings

Tickers covered

Sources

Aggregated

Latest rating

1 months ago

2026-04-30 00:00:00+00

Track record

Aggregated

43% success rate

Bullish: 0
Hold: 1
Bearish: 0

Aggregated

Not available

Bullish: 13
Hold: 2
Bearish: 1

Recent ratings

Ticker	Date	Rating	Price target	Source
TEVA	2026-04-30	buy	$45.00	Aggregated
VNDA	2026-03-05	buy	$18.00	Aggregated
AMRX	2026-03-02	buy	$17.00	Aggregated
TEVA	2026-02-18	buy	$42.00	Aggregated
TEVA	2026-01-29	buy	$38.00	Aggregated
BHC	2026-01-07	hold	$8.00	Aggregated
COLL	2025-11-07	buy	$48.00	Aggregated
PCRX	2025-11-07	buy	$28.00	Aggregated
TEVA	2025-05-28	buy	$25.00	Aggregated
TEVATEVA- PHARMACEUTICAL INDUSTRIES LTD. - ADR	2025-05-28	unknown	$25.00	Aggregated
PCRX	2025-01-30	hold	$25.00	Aggregated
PCRXPACIRA BIOSCIENCES INC	2025-01-30	hold	$25.00	Aggregated
AMRX	2024-10-02	buy	$12.00	Aggregated
AMRXAMNEAL PHARMACEUTICALS INC - ORDINARY SHARES - CLASS A	2024-10-02	unknown	$12.00	Aggregated
PCRX	2024-08-13	sell	$8.00	Aggregated
AMRX	2024-08-12	buy	$10.00	Aggregated
COLL	2024-08-09	buy	$42.00	Aggregated
AMRX	2024-05-06	buy	$9.00	Aggregated
COLL	2024-02-26	buy	$40.00	Aggregated

Tickers covered(9)

Ticker	Ratings	Last rating	Sources
TEVA	4	2026-04-30	Aggregated
VNDA	1	2026-03-05	Aggregated
AMRX	4	2026-03-02	Aggregated
BHC	1	2026-01-07	Aggregated
COLL	3	2025-11-07	Aggregated
PCRX	3	2025-11-07	Aggregated
TEVATEVA- PHARMACEUTICAL INDUSTRIES LTD. - ADR	1	2025-05-28	Aggregated
PCRXPACIRA BIOSCIENCES INC	1	2025-01-30	Aggregated
AMRXAMNEAL PHARMACEUTICALS INC - ORDINARY SHARES - CLASS A	1	2024-10-02	Aggregated

Methodology differs by source. Track records are aggregated from multiple sources; scoring methodology and scales differ by source and values are not directly comparable. Coverage is sourced from publicly-aggregated analyst activity. Past performance does not guarantee future results. Not investment advice.